Have just voted with Sernova management. 
Sernova, on a very limited budget, has developed a world class pharmaceutical product (The Pouch) and is working on a companion product (stem cell related developments) that would appear to be well advanced (per 24 March 2020 news). 
Some of our key initiatives for 2020 include:
-
- Focusing on patient enrollment completion which includes Cell Pouch implantation and the continued advancement of our US Phase I/II Cell Pouch Clinical Trial;
- Evolving stem cell-derived islet technologies, with the end goal to provide an unlimited supply of stem cell-derived islet cells for the anticipated treatment of any person inflicted with insulin-dependent diabetes;
- Continuing the evaluation of alternative novel local immune protection technologies for therapeutic cells, to be used in conjunction with our Cell Pouch technologies, for potential in-licensing or acquisition;
- Advancing further IND enabling preclinical proof of concept studies for the treatment of postoperative hypothyroid disease;
- Developing additional collaborations with pharma companies; and
- Releasing results of our research through publications in peer-reviewed scientific journals and conferences.
"While COVID-19 has introduced uncertainties for all people and businesses worldwide, we are proactively evolving how we operate and are adopting alternative methods and approaches to enable us to carry on our business and the US Phase I/II Cell Pouch Clinical Trial with the goal of mitigating potential impact. We are also continuing to advance our scientific, clinical and business activities within the context of the COVID-19 situation and are committed to following the evolving guidelines recommended by WHO, CDC, and the Federal and Provincial Governments of Canada to protect the safety of our employees and families, collaborators and business partners," said Dr. Philip Toleikis. He continued, "Despite the current environment, we are focused and committed to build upon our recent clinical and preclinical program achievements towards further important advancements in 2020 to deliver long-term value to our shareholders."
Although I would like more information and more frequently, sic, the recent news (24 March 2020) clearly showed Sernova is moving forward, including with the FDA trial, even with a COVID-19 lock-down almost everywhere. The FDA trial has multiple candidates (my guess is three cohorts; one now a year on) test driving The Pouch. Results to date have been World First, lest readers forget, and will lead to disruptive medicine, a paradigm shift, for diabetics. 
My take is this kind of progress on virtually peanuts requires shareholders to vote with management, especially in these very trying times. Shareholders need to show management their support for what has been accomplished and what is indicated to come.
Some have suggested to vote against management with no basis in fact. None has been able to provide any evidence that other companies have done far better on less money than Sernova. One can show any number of companies ((large and small), especially Oil and Gas and other resource ones, that have thrown megabucks away and delivered very little.
Some useful links (for information) are provided below.
AGM Circular
Attention re: COVID-19:
4. NOTE OF CAUTION Concerning COVID-19 Outbreak At the date of this Notice and the accompanying Circular it is the full intention of the Corporation to hold the Meeting at the location stated above in this Notice, where, if they choose, shareholders can attend the Meeting in person. However, we are continuously monitoring the current coronavirus (COVID-19) outbreak (“COVID-19”), and in light of the rapidly evolving news and public health guidelines related to COVID-19, we ask shareholders wishing to attend the Meeting in person, to carefully consider and follow the instructions of the federal Public Health Agency of Canada: (https://www.canada.ca/en/public-health/services/diseases/coronavirus-disease-covid19.html). We also ask that shareholders review and follow the instructions of any regional health authorities of the Province of British Columbia, including the Vancouver Coastal Health Authority, the Fraser Health Authority and any other health authority holding jurisdiction over the areas you must travel through to attend the Meeting. Please do not attend the Meeting in person if you are experiencing any cold or flu-like symptoms, or if you or someone with whom you have been in close contact has travelled to/from outside of Canada within the 14 days immediately prior to the Meeting. All shareholders are strongly encouraged to vote by submitting their completed form of proxy (or voting instruction form) prior to the Meeting by one of the means described on pages 2 to 3 of the Circular accompanying this Notice.
Please be aware that the Corporation reserves the right to take any additional precautionary measures deemed to be appropriate, necessary or advisable in relation to the Meeting in response to further developments in the COVID-19 outbreak, including: (i) holding the Meeting solely by providing a webcast of the Meeting; (ii) hosting the Meeting solely by means of remote communication; (iii) changing the Meeting date and/or changing the means of holding the Meeting. Should any such changes to the Meeting format occur, the Corporation will announce any and all of these changes by way of news release, which will be filed under the Corporation’s profile on SEDAR as well as on our Corporation’s website at www.sernova.com. We strongly recommend you check our Corporation’s website regularly and at least one week prior to the Meeting date for the most current information. In the event of any changes to the Meeting format due to the COVID-19 outbreak, the Corporation will not prepare or mail amended proxy materials.
Proxy and how to vote including by Internet
Notice - Access for AGM
jwall
